---
title: "Sunshine Lake Pharma’s Olorigliflozin Added to China’s 2026 Reimbursement List"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/305581119.md"
description: "Sunshine Lake Pharma announced its Olorigliflozin Capsules have been included in China’s 2026 National Reimbursement Drug List, effective January 1, 2027. The drug received marketing approval in January 2026. Phase III studies demonstrated efficacy in reducing HbA1c and glucose levels with good tolerability. Additionally, the company noted that its insulin glargine received U.S. FDA approval in April 2026, making it the first Chinese pharmaceutical company to commercialize this product in the U.S."
datetime: "2026-11-15T10:38:31.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/305581119.md)
  - [en](https://longbridge.com/en/news/305581119.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/305581119.md)
generator: "portal-rs"
---

# Sunshine Lake Pharma’s Olorigliflozin Added to China’s 2026 Reimbursement List

Sunshine Lake Pharma Co., Ltd. Class H ( (HK:6887) ) has issued an announcement.

Sunshine Lake Pharma said Olorigliflozin Capsules has been included in China’s 2026 National Reimbursement Drug List. The list takes effect on 1 January 2027, while the product received marketing approval from China’s National Medical Products Administration in January 2026.

Two multicenter Phase III studies found that 24 weeks of treatment, alone or with metformin, reduced HbA1c and fasting and postprandial glucose, while also improving blood pressure and body weight. Efficacy remained stable through 52 weeks, and the product was generally well tolerated, with adverse-reaction incidence not significantly different from placebo.

The Group has seven approved insulin products, with HEC-151, an ultra-long-acting weekly formulation, in Phase I trials. Its insulin glargine received a U.S. FDA approval letter at the end of April 2026; the release said this made the company the first PRC pharmaceutical company to commercialize an insulin glargine product in the U.S. market.

### Related Stocks

- [06887.HK](https://longbridge.com/en/quote/06887.HK.md)

## Related News & Research

- [Yushuai Zhang Bought 3.8% More Shares In Sunshine Lake Pharma](https://longbridge.com/en/news/305511686.md)
- [Sunshine Lake Pharma Wins China Nod for Dual-Action Insulin, Expands Global Footprint](https://longbridge.com/en/news/301266179.md)
- [Tesla’s Cheapest Model Y Gets More Range in the U.S., But Not in Canada](https://longbridge.com/en/news/305577641.md)
- [Vishnusurya Projects and Infra's (NSE:VISHNUINFR) Weak Earnings May Only Reveal A Part Of The Whole Picture](https://longbridge.com/en/news/305559929.md)
- [Pondy Oxides And Chemicals Limited Just Missed Earnings And Its Revenue Numbers Were Weaker Than Expected](https://longbridge.com/en/news/305560101.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**